Skip to main content

Table 2 Background of the non-COVID-19 group

From: Retrospective study on the efficacy of monocyte distribution width (MDW) as a screening test for COVID-19

Ā 

Age

Male/female

WBC (Ī¼L)

CRP (mg/dL)

MDW

Total (Nā€‰=ā€‰232)

70 (13ā€“96)

109/123

6700 (500ā€“21,100)

0.565 (0.01ā€“31.46)

19.0 (13.6ā€“30.2)

Acute respiratory infection (Nā€‰=ā€‰141)

69 (15ā€“92)

67/74

7200 (500ā€“21,100)

1.59 (0.01ā€“31.46)

19.4 (15.0ā€“28.2)

Ā Mild (Nā€‰=ā€‰80)

54.5 (15ā€“92)

33/47

6550 (500ā€“21,100)

0.37 (0.01ā€“13.64)

18.9 (15.0ā€“27.2)

Ā Moderate I (Nā€‰=ā€‰52)

77.5 (15ā€“90)

30/22

9350 (2100ā€“17,900)

3.96 (0.46ā€“31.46)

20.0 (16.4ā€“28.2)

Ā Moderate II (Nā€‰=ā€‰9)

79 (35ā€“91)

4/5

6500 (3700ā€“13,800)

9.21 (0.46ā€“22.55)

21.2 (16.5ā€“25.0)

Nonrespiratory infection (Nā€‰=ā€‰19)

64 (13ā€“87)

7/12

8400 (3800ā€“18,100)

5.01 (0.03ā€“23.15)

23.0 (16.6ā€“30.2)

Viral infection (Nā€‰=ā€‰1) (generalized herpes zoster)

81

0/1

3100

1.84

27.7

After treatment for COVID-19 (Nā€‰=ā€‰11) [median time from onset to testing: 43Ā days (11ā€“140Ā days)]

68 (24ā€“75)

7/4

5500 (2600ā€“9000)

0.09 (0.02ā€“0.7)

18.1 (16.6ā€“21.7)

Contacted with COVID-19 patients (Nā€‰=ā€‰1)

21

1/0

6100

0.01

16.2

Noninfectious disease (Nā€‰=ā€‰59)

72 (17ā€“96)

26/33

5400 (3200ā€“12,800)

0.11 (0.01ā€“6.5)

18.0 (13.6ā€“21.7)

  1. Data are expressed as the median (range)
  2. WBC, white blood cell; CRP, C-reactive protein; MDW, monocyte distribution width